<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abcellera Biologics Inc. — News on 6ix</title>
<link>https://6ix.com/company/abcellera-biologics-inc</link>
<description>Latest news and press releases for Abcellera Biologics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 11 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abcellera-biologics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683540ba0eaa31f6af967793.webp</url>
<title>Abcellera Biologics Inc.</title>
<link>https://6ix.com/company/abcellera-biologics-inc</link>
</image>
<item>
<title>AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q1-2026-business-results-and-announces-positive-interim-phase-1-clinical-data-for-abcl635</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q1-2026-business-results-and-announces-positive-interim-phase-1-clinical-data-for-abcl635</guid>
<pubDate>Mon, 11 May 2026 20:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, May 11, 2026--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635</description>
</item>
<item>
<title>AbCellera to Present at Upcoming Investor Conferences in May and June 2026</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-present-at-upcoming-investor-conferences-in-may-and-june-2026</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-present-at-upcoming-investor-conferences-in-may-and-june-2026</guid>
<pubDate>Thu, 07 May 2026 20:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, May 07, 2026--AbCellera to Present at Upcoming Investor Conferences in May and June 2026</description>
</item>
<item>
<title>AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 20, 2026--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call</description>
</item>
<item>
<title>AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-report-first-quarter-2026-financial-results-on-may-11-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-to-report-first-quarter-2026-financial-results-on-may-11-2026-5</guid>
<pubDate>Wed, 01 Apr 2026 20:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 01, 2026--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026</description>
</item>
<item>
<title>AbCellera Reports Full Year 2025 Business Results</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-full-year-2025-business-results</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-full-year-2025-business-results</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, February 24, 2026--AbCellera Reports Full Year 2025 Business Results</description>
</item>
<item>
<title>AbCellera to Present at Upcoming Investor Conferences in March and April 2026</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-present-upcoming-investor-conferences-210500013</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-present-upcoming-investor-conferences-210500013</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, February 11, 2026--AbCellera to Present at Upcoming Investor Conferences in March and April 2026</description>
</item>
<item>
<title>AbCellera to Report Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-full-2025-financial-210500547</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-full-2025-financial-210500547</guid>
<pubDate>Thu, 22 Jan 2026 21:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, January 22, 2026--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026</description>
</item>
<item>
<title>AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-announces-first-patients-dosed-phase-2-portion-its-phase-1-2-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-announces-first-patients-dosed-phase-2-portion-its-phase-1-2-clinical-trial</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its</description>
</item>
<item>
<title>AbCellera and Bruker Reach Global Settlement of Patent Litigation</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-and-bruker-reach-global-settlement-patent-litigation-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-and-bruker-reach-global-settlement-patent-litigation-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement</description>
</item>
<item>
<title>AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-present-44th-annual-jp-morgan-healthcare-conference-january-14-2026-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-present-44th-annual-jp-morgan-healthcare-conference-january-14-2026-2025-12</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan</description>
</item>
<item>
<title>AbCellera Appoints Dr. Stephen Quake to its Board of Directors</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-appoints-dr-stephen-quake-its-board-directors-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-appoints-dr-stephen-quake-its-board-directors-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors</description>
</item>
<item>
<title>AbCellera Reports Q3 2025 Business Results</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q3-2025-business-results-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q3-2025-business-results-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial</description>
</item>
<item>
<title>AbCellera to Participate at Upcoming Investor Conferences in November and December 2025</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-participate-upcoming-investor-conferences-november-and-december-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-participate-upcoming-investor-conferences-november-and-december-2025-2025</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor</description>
</item>
<item>
<title>AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-third-quarter-2025-financial-results-november-6-2025-2025-09-29</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-third-quarter-2025-financial-results-november-6-2025-2025-09-29</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025,</description>
</item>
<item>
<title>AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-appoints-dr-sarah-noonberg-chief-medical-officer-2025-09-10</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-appoints-dr-sarah-noonberg-chief-medical-officer-2025-09-10</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical</description>
</item>
<item>
<title>AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-doses-first-participants-phase-1-clinical-trial-abcl575-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-doses-first-participants-phase-1-clinical-trial-abcl575-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis VANCOUVER,</description>
</item>
<item>
<title>AbCellera to Participate at Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-participate-upcoming-investor-conferences-september-2025-08-12</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-participate-upcoming-investor-conferences-september-2025-08-12</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor</description>
</item>
<item>
<title>AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q2-2025-business-results-first-participants-dosed-phase-1-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-reports-q2-2025-business-results-first-participants-dosed-phase-1-clinical</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has</description>
</item>
<item>
<title>AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-second-quarter-2025-financial-results-august-7-2025-2025-07-07</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-report-second-quarter-2025-financial-results-august-7-2025-2025-07-07</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025,</description>
</item>
<item>
<title>AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575</title>
<link>https://6ix.com/company/abcellera-biologics-inc/news/abcellera-receives-authorization-health-canada-initiate-phase-1-clinical-trial-0</link>
<guid isPermaLink="true">https://6ix.com/company/abcellera-biologics-inc/news/abcellera-receives-authorization-health-canada-initiate-phase-1-clinical-trial-0</guid>
<pubDate>Fri, 30 May 2025 04:00:00 GMT</pubDate>
<description>ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera</description>
</item>
</channel>
</rss>